Somatropin Market Size Analysis, Business Scope, Drivers and Growth Opportunities
Human
growth hormone (HGH), also known as somatotropin, is a peptide hormone that
stimulates growth, cell reproduction, and cell regeneration in humans, making
it essential for human development. In humans, growth hormone (GH) deficiency
occurs when the pituitary gland fails to synthesize a sufficient concentration
of hGH. In humans, this deficiency is treated with subcutaneous injections of
recombinant human growth hormone. Human growth hormone deficiency can be caused
by a variety of genetic disorders, including Prader-Willi syndrome and Turner
syndrome, and can result in delayed puberty and shorter-than-average height.
Somatropin market deficiency occurs when the pituitary gland
fails to synthesize sufficient concentrations of human growth hormones. This
deficiency is treated with subcutaneous injections of recombinant human growth
hormones. Growth hormone deficiency can also be caused by genetic disorders
such as Prader-Willi syndrome and Turner syndrome, resulting in delayed puberty
and shorter-than-average height.
HGH is
a peptide hormone that the pituitary gland produces to stimulate growth in
children and adults. The hormone primarily regulates cell growth, regeneration,
repair, reproduction, and metabolism, thereby contributing to overall body
development. It also controls body fluids, fat metabolism, bone and muscle
growth, and so on. HGH deficiency increases the risk of disease and fat
accumulation, whereas high levels cause gigantism in children and acromegaly,
muscle-wasting disease, and short bowel syndrome in adults.
In
recent years, the global somatropin market has grown significantly. This expansion is
attributed to an increase in disorders associated with a growth hormone
deficiency, increased growth hormone usage to control aging, government and
private sector initiatives to raise awareness about growth hormone deficiency,
and a robust product portfolio.
Other
factors such as increased awareness of the treatment procedure, an increase in
the number of health disorders, and an increase in neuropsychiatric cases will
drive the human growth hormone market.
Sandoz, F. Hoffmann-La Roche AG, Pfizer, Eli
Lilly and Company, Novo Nordisk, Merck Co., and others are among the market
leaders in the global somatropin market.
Comments
Post a Comment